AJ Pharma completes Danish vaccine business acquisition

KUALA LUMPUR: AJ Pharma Group has completed its first global vaccine business acquisition in Denmark, creating an independent vaccine production business through the government-owned Statens Serum Institut (SSI).

In a statement yesterday, AJ Pharma said upon acquisition, the SSI has been renamed AJ Vaccines.

“The completion of this acquisition is a significant milestone in the AJ Pharma Group's global strategy to create a stronger presence in the vaccine market across the world.

“Most significantly, AJ Vaccines complements the group's ongoing project to establish a vaccine formulation, fill and finish facility in Malaysia through AJ Biologics Sdn Bhd,” it said AJ Vaccines Chairman Dr Tabassum Khan said the acquisition now brings the group a step closer to achieving its vision of becoming a top vaccine player globally.

“Together with our ongoing project, which is to establish a vaccine formulation, fill and finish facility in Malaysia, we are now in a prime position to achieve economic, social and humanitarian objectives for Malaysia and beyond,” he added. — Bernama